Alvespimycin (17-DMAG) HCl

製品コードS1142 別名:NSC 707545,BMS 826476 HCl,KOS 1022

Alvespimycin (17-DMAG) HCl化学構造

分子量(MW):653.21

Alvespimycin (17-DMAG) HClは一種の有効なHSP90阻害剤で、無細胞試験でIC50値が62 nMです。臨床2期。

サイズ 価格 在庫  
USD 172 あり
USD 189 あり
USD 466 あり
USD 718 あり

カスタマーフィードバック(5)

  • H2228/Vec or H2228/HGF cells were treated with or without alectinib (0.3 μmol/L) for 2 h or 17-DMAG (0.3 μmol/L) for 24 h and then stimulated with or without HGF (50 ng/mL) for 10 minutes. The resultant cells were lysed, and the indicated proteins were detected by immunoblotting.

    Oncotarget, 2014, 5(13): 4920-28 . Alvespimycin (17-DMAG) HCl purchased from Selleck.

    H2228 cells were treated with or without alectinib (0.3 μmol/L) for 2 h or 17-DMAG (0.3 μmol/L) for 24 h, and then stimulated with or without EGF (100 ng/mL), HB-EGF (10 ng/mL), and TGF-α (100 ng/mL) for 10 min. The resultant cells were lysed, and the indicated proteins were detected by immunoblotting.

    Oncotarget, 2014, 5(13): 4920-28 . Alvespimycin (17-DMAG) HCl purchased from Selleck.

  • Mol Oncol 2013 7(6), 1093-102. Alvespimycin (17-DMAG) HCl purchased from Selleck.

    17-DMAG suppresses EGF and Met protein expression and phosphorylation even in the presence of HGF. PC-9, Ma-1, Ma-1/Vec, and Ma-1/HGF tumor cells were treated with or without erlotinib (0.3 umol/l) or 17-DMAG (0.3 umol/l) for 24 hours, and then stimulated with or without HGF (20 ng/ml) for 10 minutes. The resultant cells were lysed, and the indicated proteins were detected by immunoblotting. EGF, epidermal growth factor; HGF, hepatocyte growth factor.

    J Thorac Oncol 2012 7(7), 1078-85. Alvespimycin (17-DMAG) HCl purchased from Selleck.

  • 17-DMAG overcomes HGF-induced erlotinib resistance in vivo. Ma-1/Vec or Ma-1/HGF cells (5 x 106 each) were inoculated subcutaneously into SCID mice on day 0. Mice received oral erlotinib (20 mg/kg/day) or intraperitoneal 17-DMAG (10 mg/kg/day), starting on day 7. Tumor size was measured twice a week and tumor volumes were calculated as described in Materials and Methods. Macroscopic appearances of representative tumors harvested on day 21. *p < 0.01 compared with the control group (Student’s t test). 17-DMAG, 17-Dimethylaminoethylamino-17-demethoxygeldanamycin; HGF, hepatocyte growth factor; SCID, severe combined immunodeficiency.

    J Thorac Oncol 2012 7(7), 1078-85. Alvespimycin (17-DMAG) HCl purchased from Selleck.

製品安全説明書

HSP (e.g. HSP90)阻害剤の選択性比較

生物活性

製品説明 Alvespimycin (17-DMAG) HClは一種の有効なHSP90阻害剤で、無細胞試験でIC50値が62 nMです。臨床2期。
特性 A synthetic derivative Geldanamycin, with lower hepatotoxicity than parent antibiotic & higher potency and bioavailability than the similar derivative 17-AAG.
ターゲット
HSP90 [1]
(Cell-free assay)
62 nM
体外試験

17-DMAG displays ~2 times potency against human Hsp90 than 17-AAG, with IC50 of 62 nM versus 119 nM. In SKBR3 and SKOV3 cells which over-express Hsp90 client protein Her2, 17-DMAG causes down-regulation of Her2 with EC50 of 8 nM and 46 nM, respectively, as well as induction of Hsp70 with EC50 of 4 nM and 14 nM, respectively, leading to significant cytotoxicity with GI50 of 29 nM and 32 nM, respectively, consistent with Hsp90 inhibition. [1] 17-DMAG in combination with vorinostat synergistically induces apoptosis of the cultured MCL cells as well as primary MCL cells, more potently than either agent alone, by markedly attenuating the levels of cyclin D1 and CDK4, as well as of c-Myc, c-RAF and Akt. [3] In contrast to 17-AAG which is only active for IKKβ in chronic lymphocytic leukemia (CLL) cells, 17-DMAG treatment effectively leads to depletion of the Hsp90 client protein, resulting in diminished NF-κB p50/p65 DNA binding, decreased NF-κB target gene transcription, and caspase-dependent apoptosis. By targeting the NF-κB family, 17-DMAG selectively mediates dose- and time-dependent cytotoxicity against CLL cells, but not normal T cells or NK cells important for immune surveillance. [5]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human A2058 cells MWrDfZRwfG:6aXRCpIF{e2G7 M2TMcWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGEzODV6IHPlcIx{KGK7IF3UWEBie3OjeTygTWM2OD1{LkGgcm0> NED1dYUyQDl{OUS4Oi=>
human AGS cells M4TIe2Z2dmO2aX;uJIF{e2G7 NWHXW4oyUW6qaXLpeIlwdiCxZjDofZBwgGmjLXnu[JVk\WRiSFnGNUBi[3SrdnH0bY9vKGmwIHj1cYFvKEGJUzDj[YxteyCkeTDy[ZBwenSncjDn[Y5mKGG|c3H5MEBKSzVyPUOuOkBvVQ>? NFLmS4MyQDN3OU[zNS=>
SKBR3 cells NGP5S2RHfW6ldHnvckBie3OjeR?= M4O1OXVxemWpdXzheIlwdiCxZjDId5A4OCCrbjDTT2JTOyClZXzsd{whTUN3ME20JI5O M1frW|E3QDV2ME[2
human MDA-MB-231 cells NIjERWRHfW6ldHnvckBie3OjeR?= M{P5S2lvcGmkaYTpc44hd2ZiSIPwPVAhcW5iaIXtZY4hVUSDLV3CMVI{OSClZXzsd{Bie3Onc4Pl[EBieyCqZYKyJIRm\3KjZHH0bY9vNCCLQ{WwQVQvPSCwTR?= NV3ORY5QOTh7Mkm0PFY>
human MDA-MB-231 cells NXvMeY0yS3m2b4TvfIlkyqCjc4PhfS=> NGjUUpJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIJ6KE2WVDDhd5NigSxiSVO1NF02Njhibl2= MnvCNVg6Ojl2OE[=
human A2058 cells NWXtUIhsTnWwY4Tpc44h[XO|YYm= MoPFTY5pcWKrdHnvckBw\iCKc4C5NEBqdiCqdX3hckBCOjB3ODDj[YxteyxiRVO1NF04Njlibl2= MkTONVg6Ojl2OE[=
SKOV3 cells M1W1UmZ2dmO2aX;uJIF{e2G7 NFnKbllWeHKnZ4XsZZRqd25ib3[gTJNxPzBiaX6gV2tQXjNiY3XscJMtKEWFNUC9NVQhdk1? Mm[yNVY5PTRyNk[=
SKBr3 cells MVLDfZRwfG:6aXRCpIF{e2G7 M37VXmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KFONQoKzJINmdGy|LDDJR|UxRTJ2IH7N MWCxOlE3PTN3NB?=
human AGS cells MY\GeY5kfGmxbjDhd5NigQ>? MmDCNVYhcA>? MnLvTY5pcWKrdHnvckBw\iCKSV[xJIFkfGm4YYTpc44hcW5iaIXtZY4hSUeVIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhcHmyb4jpZU1qdmS3Y3XkJIx2[2moZYLhd4Uh\XiycnXzd4lwdiCjZoTldkAyPiCqcoOgZpkhemWyb4L0[ZIh[XO|YYmsJGlEPTB;M{[gcm0> NUW3Um5POTd3OEO5OVA>
human HCT116 cells NHnEW21EgXSxdH;4bYPDqGG|c3H5 MXfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[nliQXzhcYFzKGKudXWgZZN{[XluIFnDOVA:PTBibl2= NYfyT4JOOjB4NkK1N|Q>
human Hep3B cells MYXGeY5kfGmxbjDhd5NigQ>? MmHrNVIhcA>? MnKxTY5pcWKrdHnvckBw\iCqeYDvfIliNWmwZIXj[YQhUEmIMXHsdIhiKHC{b4TlbY4h[WOldX31cIF1cW:wIHnuJIh2dWGwIFjldFNDKGOnbHzzJJRz\WG2ZXSg[o9zKDNyIH3pcpMhdWWjc4Xy[YQh[W[2ZYKgNVIhcHK|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqeyxiSVO1NF02PyCwTR?= Mn:0NlA1Pjl6OEe=
human A549 cells MlvuR5l1d3SxeHnjxsBie3OjeR?= MlzOO|IhcA>? NUPqWY13S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA4OiCqcoOgZpkh[2WubITpeIVzNWeubzDhd5NigSxiSVO1NF03QCCwTR?= M{TYdFE6PDB3NUK4
human MCF7 cells NEn4cWxEgXSxdH;4bYPDqGG|c3H5 MnT3O|IhcA>? NXW1VmY6S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCjZoTldkA4OiCqcoOsJGlEPTB;N{Ggcm0> NX[wZlZuOTl{M{G4OlQ>
human NCI-H1299 cells MknmSpVv[3Srb36gZZN{[Xl? MmG2TY5pcWKrdHnvckBw\iCqdX3hckBJW1B7MDDpckBpfW2jbjDOR2kuUDF{OUmgZ4VtdHNiYYPz[ZN{\WRiYYOgRYt1KGSnZ4Lh[IF1cW:wIHHmeIVzKDJ2IHjyd{BjgSCudX3pcoV5KGG|c3H5MEBKSzVyPUCuNUDPxE1? MoLnNlE1Ozh3NEG=
human HeLa cells MorISpVv[3Srb36gZZN{[Xl? M2K3RmlvcGmkaYTpc44hd2ZiVF7GMYFteGijLXnu[JVk\WRiTl[tb4FxeGGEIHHjeIl3[XSrb36gbY4hcHWvYX6gTIVN[SClZXzsd{whUUN3ME2wMlE2KM7:TR?= MX:xPFM2QTZ|MR?=
human A231 cells MXLQdo9tcW[ncnH0bY9vKGG|c3H5 NVe5WWRHPDhiaB?= MlXyRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCDMkOxJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5zNzFOwG0> NXv0dJo5OjR5NkOyOlE>
human CCRF-CEM cells M2LxNGN6fG:2b4jpZ:Kh[XO|YYm= MlW4O|IhcA>? Mn\QR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR2NTTi2FRV2gZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KGOnbHz0bZRmei17NjDhdZVmd3W|IH;u[UB{d2y3dHnvckBie3OjeTygTWM2OD1yLkW0JO69VQ>? NYXBSIdQOTl2MEW1Nlg>
human NCI-H596 cells NGnQfGREgXSxdH;4bYPDqGG|c3H5 NEK4XGo4OiCq NYPCVXY{S3m2b4TvfIlkcXS7IHHnZYlve3RiTmGwNU1l\W[rY3nlcpQhcHWvYX6gUmNKNUh3OU[gZ4VtdHNiYX\0[ZIhPzJiaILzMEBKSzVyPUGuNUDPxE1? NIPk[|MyQTJ|MUi2OC=>
human HCT116 cells NWnqbXlUWHKxbHnm[ZJifGmxbjDhd5NigQ>? MmrhOFghcA>? Mn;0RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKQ2SxNVYh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1zLkKxJO69VQ>? NIj2eIwzPDd4M{K2NS=>
human MDA468 cells NEHC[lZEgXSxdH;4bYPDqGG|c3H5 MWe3NkBp MWfDfZRwfG:6aXPpeJkh[WejaX7zeEBPWTBzLXTl[olkcWWwdDDoeY1idiCPRFG0Olgh[2WubIOgZYZ1\XJiN{KgbJJ{NCCLQ{WwQVEvPiEQvF2= NEj4S|IyQTJ|MUi2OC=>
human AGS cells NHHuPFZEgXSxdH;4bYPDqGG|c3H5 MXPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBS3Mh[2WubIOgZpkhVVSWIHHzd4F6NCCLQ{WwQVE3KM7:TR?= MkHQNVg{PTl4M{G=
human LN229-Lux cells M4rxN2Z2dmO2aX;uJIF{e2G7 NHXXd5QzNjVvMUCg{txO MlHTNUBp NEfLdXpKdmirYnn0bY9vKG:oIHz1Z4ln\XKjc3WgZYN1cX[rdImgbY4hcHWvYX6gUG4zOjlvTIX4JINmdGy|IHH0JFIvPSC2bzCxNEB2VSCrbnP1ZoF1\WRiZn;yJFEhcHJidX7k[ZIhdm:{bX;4bYEh\m:ubH;3[YQh[nliMkSgbJJ{KHWwZHXyJIh6eG:6aXGgZpkhemWyb4L0[ZIh\2WwZTDhd5NigQ>? NHHtZY8zOjd2NkK3OC=>
human NCI-H1299 cells NELKWINHfW6ldHnvckBie3OjeR?= MkX6NVIhcA>? M1XIZXJm\HWldHnvckBqdiCxeInn[Y4h[2:wc4XtdJRqd25icnH0[UBqdiCqdX3hckBPS0lvSEGyPVkh[2WubIOgbY5kfWKjdHXkJIZweiBzMjDodpM> M3XP[FI2Ozh|OUG1
human NCI-H526 cells MoDvSpVv[3Srb36gZZN{[Xl? MUCxJO69VQ>? NFPzUnozPCCq NU\iVFBnSmmwZHnu[{Bi\m[rbnn0fUB1dyCKU2C5NEBqdiCqdX3hckBPS0lvSEWyOkBk\WyuczDheEAyKHWPIHHmeIVzKDJ2IHjyd{BjgSCobIXvdoV{[2WwY3WgdI9t[XKrenH0bY9vKGG|c3H5 MV[xO|YxOzV2MB?=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 17-DMAG treatment at 5 mg/kg or 25 mg/kg thrice per week significantly reduces tumor growth of TMK-1 xenografts, by significantly reducing vessel area and numbers of proliferating tumor cells in sections. [2] Consistent the inhibition of FAK signaling in vivo, 17-DMAG treatment at 25 mg/kg three times a week significantly suppresses tumor growth, and metastasis of ME180 and SiHa xenografts in mice. [4] Administration of 17-DMAG at 10 mg/kg for 16 days significantly decreases the white blood cell count and prolongs the survival in a TCL1-SCID transplant mouse model. [5]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
+ 展開

Fluorescence polarization (FP)-based competition binding assay:

This assay utilizes a boron difluoride dipyrromethene (BODIPY) labeled geldanamycin analogue (BODIPY-AG) as a probe and measured fluorescence polarization upon binding of the probe to a protein. Native human Hsp90 protein (α + β isoforms) is isolated from HeLa cells. BODIPY-AG solution is freshly prepared in FP assay buffer (20 mM HEPES-KOH, pH 7.3, 1.0 mM EDTA, 100 mM KCl, 5.0 mM MgCl2, 0.01% NP-40, 0.1 mg/mL fresh bovine γ-globulin (BGG), 1.0 mM fresh DTT, and protease inhibitor from stock solution in DMSO. Competition curves are obtained by mixing 10 μL each of a solution containing BODIPY-AG and Hsp90, and a serial dilution of 17-DMAG freshly prepared in FP assay buffer from stock solution in DMSO. Final concentrations are 10 nM BODIPY-AG, 40 or 60 nM Hsp90, varying concentration of 17-DMAG (0.10 nM-10 μM), and ≤0.25% DMSO in a 384-well microplate. After 3 hours incubation at 30 °C, fluorescence anisotropy (γEx = 485 nm, γEm = 535 nm) is measured on an EnVision 2100 multilabel plate reader. IC50 value of 17-DMAG is obtained from the competition curves.
細胞試験: [5]
+ 展開
  • 細胞株: Chronic lymphocytic leukemia (CLL)
  • 濃度: Dissolved in DMSO, final concentrations ~1 μM
  • 反応時間: 24, or 48 hours
  • 実験の流れ: Cells are exposed to various concentrations of 17-DMAG for 24, or 48 hours. For the assessment of cytotoxicity, MTT reagent is then added, and plates are incubated for an additional 24 hours before spectrophotometric measurement. Apoptosis is determined by staining with annexin V-fluorescein isothiocyanate and propidium iodide (PI).
    (参考用のみ)
動物試験:[5]
+ 展開
  • 動物モデル: SCID mice engrafted with TCL1 leukemia cells
  • 製剤: Dissolved in DMSO
  • 投薬量: 10 mg/kg
  • 投与方法: Intraperitoneal injection 5 times per week
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 131 mg/mL (200.54 mM)
Water slightly soluble or insoluble
Ethanol slightly soluble or insoluble
体内 順序で溶剤を入れること:
1% DMSO+30% polyethylene glycol+1% Tween 80
30 mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 653.21
化学式

C32H48N4O8•HCl

CAS No. 467214-21-7
保管
in solvent
別名 NSC 707545,BMS 826476 HCl,KOS 1022

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01126502 Terminated B-cell Chronic Lymphocytic Leukemia|Prolymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia National Cancer Institute (NCI) May 2010 Phase 1
NCT00780000 Terminated Breast Cancer Bristol-Myers Squibb April 2008 Phase 2
NCT00803556 Completed Solid Tumor|Breast Cancer Bristol-Myers Squibb January 2006 Phase 1
NCT00248521 Unknown status Unspecified Adult Solid Tumor, Protocol Specific Institute of Cancer Research, United Kingdom|National Cancer Institute (NCI) October 2005 Phase 1
NCT00089271 Completed Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Splenic Marginal Zone Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Mycosis Fungoides/Sezary Syndrome|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|Stage IV Small Lymphocytic Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Waldenström Macroglobulinemia National Cancer Institute (NCI) July 2004 Phase 1
NCT00089362 Completed Male Breast Cancer|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Breast Cancer|Recurrent Colon Cancer|Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Recurrent Gastric Cancer|Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Melanoma|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Ovarian Epithelial Cancer|Recurrent Prostate Cancer|Recurrent Renal Cell Cancer|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Stage III Adenoid Cystic Carcinoma of the Oral Cavity|Stage III Basal Cell Carcinoma of the Lip|Stage III Colon Cancer|Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage III Gastric Cancer|Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage III Lymphoepithelioma of the Nasopharynx|Stage III Lymphoepithelioma of the Oropharynx|Stage III Melanoma|Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage III Mucoepidermoid Carcinoma of the Oral Cavity|Stage III Ovarian Epithelial Cancer|Stage III Renal Cell Cancer|Stage III Salivary Gland Cancer|Stage III Squamous Cell Carcinoma of the Hypopharynx|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage III Squamous Cell Carcinoma of the Nasopharynx|Stage III Squamous Cell Carcinoma of the Oropharynx|Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage III Verrucous Carcinoma of the Larynx|Stage III Verrucous Carcinoma of the Oral Cavity|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Adenoid Cystic Carcinoma of the Oral Cavity|Stage IV Basal Cell Carcinoma of the Lip|Stage IV Breast Cancer|Stage IV Colon Cancer|Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IV Gastric Cancer|Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IV Lymphoepithelioma of the Nasopharynx|Stage IV Lymphoepithelioma of the Oropharynx|Stage IV Melanoma|Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IV Mucoepidermoid Carcinoma of the Oral Cavity|Stage IV Ovarian Epithelial Cancer|Stage IV Prostate Cancer|Stage IV Renal Cell Cancer|Stage IV Salivary Gland Cancer|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx|Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IV Verrucous Carcinoma of the Larynx|Stage IV Verrucous Carcinoma of the Oral Cavity|Unspecified Adult Solid Tumor, Protocol Specific|Untreated Metastatic Squamous Neck Cancer With Occult Primary National Cancer Institute (NCI) July 2004 Phase 1

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

HSP (e.g. HSP90)信号経路図

HSP (e.g. HSP90) Inhibitors with Unique Features

相関HSP (e.g. HSP90)製品

Tags: Alvespimycin (17-DMAG) HClを買う | Alvespimycin (17-DMAG) HCl ic50 | Alvespimycin (17-DMAG) HCl供給者 | Alvespimycin (17-DMAG) HClを購入する | Alvespimycin (17-DMAG) HCl費用 | Alvespimycin (17-DMAG) HCl生産者 | オーダーAlvespimycin (17-DMAG) HCl | Alvespimycin (17-DMAG) HCl化学構造 | Alvespimycin (17-DMAG) HCl分子量 | Alvespimycin (17-DMAG) HCl代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID